Saturday 17 October 2026
Export DFTX’s income statement to Excel — free account
Definium Therapeutics, Inc.
DFTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 188.0%, free cash flow fell 78.3% and total debt fell 11.5%, each against the same quarter a year earlier.
32.10
2.16
−6.30%
Follow DFTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
3.30 | 6.29 | 4.69 | 6.95 |
Net Debt/EBITDA |
3.71 | 7.87 | 5.67 | 13.70 | |
Debt/Assets |
17.05% | 9.22% | 10.16% | 3.28% | |
Debt/Equity |
0.31 | 0.12 | 0.15 | 0.04 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.44 | 0.85 | 0.55 | 0.33 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(35.85) | (37.52) | (47.57) | (60.89) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.08 | 0.05 | 0.05 | 0.02 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.34) | (0.48) | (0.39) | (0.48) | |
Cash per Share |
2.43 | 4.61 | 3.43 | 9.79 | |
Shareholders Equity per Share |
1.52 | 3.72 | 2.56 | 8.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.52 | 3.72 | 2.56 | 8.30 | |
Free Cash Flow |
(29.57) | (42.97) | (42.63) | (52.78) | |
Working Capital |
150.43 | 352.62 | 299.45 | 934.90 | |
Net Current Asset Value |
109.53 | 311.55 | 258.12 | 897.88 | |
| Other line items | |||||
Quick Ratio |
3.20 | 6.17 | 4.60 | 6.89 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.34) | (0.48) | (0.39) | (0.48) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.13 | 3.68 | 4.70 | 5.59 | |
Average Assets |
278.34 | 371.13 | 338.31 | 689.00 | |
Average Common Equity |
196.39 | 286.89 | 250.83 | 552.04 |
Columns are period end dates